全文获取类型
收费全文 | 1219173篇 |
免费 | 81826篇 |
国内免费 | 2060篇 |
专业分类
耳鼻咽喉 | 16832篇 |
儿科学 | 33156篇 |
妇产科学 | 29933篇 |
基础医学 | 173475篇 |
口腔科学 | 39237篇 |
临床医学 | 99590篇 |
内科学 | 246430篇 |
皮肤病学 | 26941篇 |
神经病学 | 96070篇 |
特种医学 | 44911篇 |
外国民族医学 | 106篇 |
外科学 | 186712篇 |
综合类 | 19977篇 |
现状与发展 | 2篇 |
一般理论 | 313篇 |
预防医学 | 94010篇 |
眼科学 | 27926篇 |
药学 | 92770篇 |
3篇 | |
中国医学 | 3316篇 |
肿瘤学 | 71349篇 |
出版年
2021年 | 11131篇 |
2019年 | 11572篇 |
2018年 | 17336篇 |
2017年 | 12684篇 |
2016年 | 13257篇 |
2015年 | 15159篇 |
2014年 | 20106篇 |
2013年 | 28535篇 |
2012年 | 41929篇 |
2011年 | 43664篇 |
2010年 | 24328篇 |
2009年 | 22177篇 |
2008年 | 39487篇 |
2007年 | 41687篇 |
2006年 | 41529篇 |
2005年 | 40453篇 |
2004年 | 38664篇 |
2003年 | 36624篇 |
2002年 | 34241篇 |
2001年 | 62862篇 |
2000年 | 65035篇 |
1999年 | 53929篇 |
1998年 | 12761篇 |
1997年 | 11069篇 |
1996年 | 11131篇 |
1995年 | 10260篇 |
1994年 | 9517篇 |
1993年 | 8715篇 |
1992年 | 39669篇 |
1991年 | 37803篇 |
1990年 | 36415篇 |
1989年 | 35299篇 |
1988年 | 32180篇 |
1987年 | 31213篇 |
1986年 | 29226篇 |
1985年 | 27905篇 |
1984年 | 19820篇 |
1983年 | 16799篇 |
1982年 | 8710篇 |
1979年 | 17676篇 |
1978年 | 11852篇 |
1977年 | 10200篇 |
1976年 | 8905篇 |
1975年 | 9904篇 |
1974年 | 11979篇 |
1973年 | 11448篇 |
1972年 | 10804篇 |
1971年 | 10218篇 |
1970年 | 9758篇 |
1969年 | 9313篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
81.
Weiyu Ye Anna Olsson-Brown Robert A. Watson Vincent T. F. Cheung Robert D. Morgan Isar Nassiri Rosalin Cooper Chelsea A. Taylor Umair Akbani Oliver Brain Rubeta N. Matin Nicholas Coupe Mark R. Middleton Mark Coles Joseph J. Sacco Miranda J. Payne Benjamin P. Fairfax 《British journal of cancer》2021,124(10):1661
Background Immune checkpoint blockers (ICBs) activate CD8+ T cells, eliciting both anti-cancer activity and immune-related adverse events (irAEs). The relationship of irAEs with baseline parameters and clinical outcome is unclear.Methods Retrospective evaluation of irAEs on survival was performed across primary (N = 144) and secondary (N = 211) independent cohorts of patients with metastatic melanoma receiving single agent (pembrolizumab/nivolumab—sICB) or combination (nivolumab and ipilimumab—cICB) checkpoint blockade. RNA from pre-treatment and post-treatment CD8+ T cells was sequenced and differential gene expression according to irAE development assessed.Results 58.3% of patients developed early irAEs and this was associated with longer progression-free (PFS) and overall survival (OS) across both cohorts (log-rank test, OS: P < 0.0001). Median survival for patients without irAEs was 16.6 months (95% CI: 10.9–33.4) versus not-reached (P = 2.8 × 10−6). Pre-treatment monocyte and neutrophil counts, but not BMI, were additional predictors of clinical outcome. Differential expression of numerous gene pathway members was observed in CD8+ T cells according to irAE development, and patients not developing irAEs demonstrating upregulated CXCR1 pre- and post-treatment.Conclusions Early irAE development post-ICB is associated with favourable survival in MM. Development of irAEs is coupled to expression of numerous gene pathways, suggesting irAE development in-part reflects baseline immune activation.Subject terms: Immunotherapy, Melanoma 相似文献
82.
83.
84.
85.
86.
87.
88.
Rosario Gulias-Cañizo Anell Lagunes-Guillén Arturo González-Robles Erika Sánchez-Guzmán Federico Castro-Muñozledo 《Burns : journal of the International Society for Burn Injuries》2019,45(2):398-412
Background
Since recent reports have shown that (-)-Epigallocatechin-3-gallate (EGCG) could be used for treating proliferative and inflammatory disorders, we explored its use for the management of corneal chemical burns.Materials and methods
Initially, EGCG was assayed on the rabbit corneal epithelial cell line RCE1(5T5) to establish the best testing conditions, and to avoid unwanted outcomes in the experimental animals. Then, we studied its effects on cell proliferation, cell cycle progression and cell differentiation. Afterwards, we instilled EGCG in experimental grade II corneal alkali burns in mice, three times a day up to 21 days, and evaluated by slit lamp examination and histological sections of corneal epithelial, corneal endothelial and stromal edema, as well as the presence of inflammatory cells and neovascularization.Results
EGCG reduced cell growth and led to a decline in the proportion of proliferative cells in a concentration dependent manner. At 10 μM, EGCG promoted cell differentiation, an effect not related with apoptosis or cytotoxicity. When 10 μM EGCG was instilled in corneal alkali burns in mice three times a day up to 21 days, EGCG significantly reduced corneal opacity and neovascularization. The improved clinical appearance of the cornea was associated to a controlled epithelial growth; epithelial morphology was similar to that observed in normal epithelium and contrasted with the hyperproliferative, desquamating epithelium observed in control burn wounds. EGCG reduced corneal, stromal and endothelial edema, and wound inflammation.Conclusion
This work constitutes the first evidence for the use of EGCG in the acute phase of a corneal alkali burn, representing a possible novel alternative to improve patient outcomes as an add-on therapy. 相似文献89.
90.